8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 1, 2011)

Filed November 1, 2011For Securities:ALNY

Summary

This 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) on November 1, 2011, primarily serves to announce the company's financial results for the third quarter ended September 30, 2011. The filing itself does not contain the detailed financial figures but rather furnishes a press release (Exhibit 99.1) where these results are disclosed. Investors should refer to the accompanying press release for specific performance metrics, including revenue, net loss, and any updates on the company's pipeline and strategic initiatives during the reported quarter. As this filing is an 8-K focused on reporting earnings, it represents a routine update on the company's financial condition and operational performance. The information is furnished and not deemed "filed" for certain regulatory purposes, which is a standard practice for earnings press releases. Investors seeking a comprehensive understanding of Alnylam's financial health and operational progress for Q3 2011 should consult the detailed information within the provided press release.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. (ALNY) filed a Form 8-K on November 1, 2011.
  • 2The primary purpose of the filing is to announce the company's financial results for the third quarter ended September 30, 2011.
  • 3The detailed financial results and operational updates are provided in a press release, furnished as Exhibit 99.1.
  • 4The filing itself does not contain the specific financial figures but directs investors to the press release for comprehensive details.
  • 5This report is a routine disclosure of quarterly financial performance.
  • 6The information furnished in this Form 8-K (including Exhibit 99.1) is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, except as specifically incorporated by reference into future filings.

Frequently Asked Questions

The main purpose of this 8-K filing by Alnylam Pharmaceuticals, Inc. is to officially announce and provide access to the company's financial results for the third quarter ended September 30, 2011. The detailed results are contained in a press release furnished as an exhibit.

The detailed financial results for the quarter ended September 30, 2011, are presented in the press release issued by Alnylam Pharmaceuticals, Inc. on November 1, 2011, which is included as Exhibit 99.1 to this Form 8-K filing.

No, the Form 8-K itself does not list the specific financial figures. It serves as a notification and filing mechanism for the press release (Exhibit 99.1), which contains the detailed financial performance data for the quarter.

The information in this Form 8-K, including the press release, is furnished and generally not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same liabilities as a formally filed document, unless specifically incorporated by reference into other SEC filings.